AI assistant
Black Diamond Therapeutics, Inc. — Director's Dealing 2021
Nov 29, 2021
33652_dirs_2021-11-29_43f231a8-42d0-4014-8d00-81f3d4b40fa4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-11-18
Reporting Person: Jones Erika (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.86 | 2029-12-04 | Common Stock (25502) | Direct | |
| Stock Option (Right to Buy) | $19 | 2030-01-28 | Common Stock (10000) | Direct | |
| Stock Option (Right to Buy) | $24.84 | 2031-03-07 | Common Stock (10800) | Direct | |
| Stock Option (Right to Buy) | $7.73 | 2031-10-17 | Common Stock (4500) | Direct | |
| Stock Option (Right to Buy) | $7.62 | 2031-11-15 | Common Stock (4500) | Direct |
Footnotes
F1: 25% of the shares subject to this option vested and became exercisable on October 28, 2020, with the reminder vesting in 36 equal monthly installments thereafter.
F2: 25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
F3: 25% of the shares subject to this option shall vest and become exercisable on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
F4: The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on October 18, 2022.
F5: The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on November 16, 2022.